NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Tofacitinib for treating moderate to severe active rheumatoid arthritis after the failure of disease-modifying anti-rheumatic drugs [ID526]

Matrix of consultees and commentators

Manufacturers/sponsors Pfizer (tofacitinib) Patient/carer groups Action on Pain Arthritis Action Arthritis & Musculoskeletal Alliance Arthritis & Musculoskeletal Alliance Arthritis Care BackCare Disability Rights UK Leonard Cheshire Disability Muslim Council of Britain National Rheumatoid Arthritis Society Pain Concern Pain Relief Foundation Pain Belief Foundation Pain Belief Foundation Pain Belief Foundation Pain UK South Asian Health Foundation Specialised Healthcare Alliance Professional groups Association of Surgeons of Great Britain British Institute of Musculoskeletal Medicine British Institute of Radiology British Pain Society British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Board of Community Health Councils in Wales Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Permulath, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Health, Sociaty National Permulath, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Permus (Station of Primary Care National Permus (Station of Health, Sociaty National Permus (Station of Primary Care National Permus (Medicines Unit NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium Scottish Medicines Consortium Pain Leathroare (Mehotrexate) Biogen Idec (etanercept) British Institute of Measociation Physiot	Consultees	Commentators (no right to submit or appeal)
 Pfizer (tofacitinib) Patient/carer groups Action on Pain Arthritis Action Arthritis Action Arthritis Care BackCare Disability Rights UK Leonard Cheshire Disability Muslim Council of Britain National Rheumatoid Arthritis Society Pain Concern Pain Relief Foundation Pain UK South Asian Health Foundation Specialised Healthcare Alliance Professional groups Association of Surgeons of Great Britain British Institute of Musculoskeletal Medicine British Institute of Radiology British Orthopaedic Association British Society for Rheumatology British Society for Rheamatoid Arthritis Surgical Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Negulatory Agency National Pharmacy Association of Primary Care National Pharmacy Association of Primary Care<td>Manufacturers/sponsors</td><td>General</td>	Manufacturers/sponsors	General
 BackCare Disability Rights UK Leonard Cheshire Disability Muslim Council of Britain National Rheumatoid Arthritis Society Pain Concern Pain Relief Foundation Pain UK South Asian Health Foundation Specialised Healthcare Alliance Professional groups Association of Surgeons of Great Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Roche (tocilizumab, rituximab) Roche (tocilizumab, rituximab) Roche (tocilizumab, rituximab) 	 Pfizer (tofacitinib) Patient/carer groups Action on Pain Arthritis Action Arthritis & Musculoskeletal Alliance 	 Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland
 Muslim Council of Britain National Rheumatoid Arthritis Society Pain Concern Pain Relief Foundation Pain UK South Asian Health Foundation Specialised Healthcare Alliance Professional groups Association of Surgeons of Great Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Pain Society British Pain Society of Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists National Pharmacy Association NHS Commercial Medicines Unit NHS Comfederation Public Health Wales NHS Trust Scottish Medicines Consortium PabbVie (adalimumab) Accord Healthcare (methotrexate) Biogen Idec (etanercept) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Merck Sharp and Dohme (infliximab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	BackCareDisability Rights UK	Medicines and Healthcare products Regulatory Agency
 Pain Relief Foundation Pain UK South Asian Health Foundation Specialised Healthcare Alliance Professional groups Association of Surgeons of Great Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Royal College of Anaesthetists NHS Confederation Public Health Wales NHS Trust Scottish Medicines Consortium Accord Healthcare (methotrexate) Amdipharm Mercury Company (methotrexate) Biogen Idec (etanercept) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Merck Sharp and Dohme (infliximab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	Muslim Council of BritainNational Rheumatoid Arthritis Society	National Pharmacy AssociationNHS Alliance
 South Asian Health Foundation Specialised Healthcare Alliance Professional groups Association of Surgeons of Great Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Orthopaedic Association British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Scottish Medicines Consortium AdbVie (adalimumab) Accord Healthcare (methotrexate) Amdipharm Mercury Company (methotrexate) Biogen Idec (etanercept) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Medac (methotrexate, infliximab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	Pain Relief Foundation	NHS Confederation
 Professional groups Association of Surgeons of Great Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Orthopaedic Association British Pain Society British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Royal College of Anaesthetists AbbVie (adalimumab) Accord Healthcare (methotrexate) Amdipharm Mercury Company (methotrexate) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	South Asian Health Foundation	
 Association of Surgeons of Great Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Accord Healthcare (methotrexate) Bridgen Idec (etanercept) Bristol-Myers Squibb (abatacept) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 		Comparator manufacturer(s)
 Britain British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Amdipharm Mercury Company (methotrexate) Biogen Idec (etanercept) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	Professional groups	,
 British Geriatrics Society British Institute of Musculoskeletal Medicine British Institute of Radiology British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists (methotrexate) Biogen Idec (etanercept) Hameln pharmaceuticals(methotrexate) Hospira UK (methotrexate, infliximab) Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 		· · · · · · · · · · · · · · · · · · ·
 British Institute of Musculoskeletal Medicine British Institute of Radiology British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Biogen Idec (etanercept) Bristol-Myers Squibb (abatacept) HameIn pharmaceuticals(methotrexate) Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 		
 British Institute of Radiology British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists HameIn pharmaceuticals(methotrexate) Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab) Napp Pharmaceuticals(methotrexate, infliximab) Merck Sharp and Dohme (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	British Institute of Musculoskeletal	Biogen Idec (etanercept)
 British Orthopaedic Association British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Hospira UK (methotrexate, infliximab) Merck Sharp and Dohme (infliximab, golimumab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 		,
 British Pain Society British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Medac (methotrexate, leflunomide) Merck Sharp and Dohme (infliximab, golimumab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 		
 British Society for Rheumatology British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Merck Sharp and Dohme (infliximab, golimumab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	·	
 British Society of Rehabilitation Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists golimumab) Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	7	
 Medicine Physiotherapy Pain Association Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Napp Pharmaceuticals (infliximab) Orion Pharma (methotrexate) Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	,	· · · · · · · · · · · · · · · · · · ·
 Primary Care Rheumatology Society Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists Pfizer (methotrexate, sulfasalazine, etanercept) Roche (tocilizumab, rituximab) 	Medicine	Napp Pharmaceuticals (infliximab)
 Rheumatoid Arthritis Surgical Society Royal College of Anaesthetists etanercept) Roche (tocilizumab, rituximab) 		,
Royal College of Anaesthetists Roche (tocilizumab, rituximab)	, ,	,
		• /
Royal College of General Practitioners		

National Institute for Health and Care Excellence

Matrix for the technology appraisal of Tofacitinib for treating moderate to severe active rheumatoid arthritis after the failure of disease-modifying anti-rheumatic drugs

Issue date: March 2017 Page 1 of 3

Consultees	Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers United Kingdom Clinical Pharmacy Association 	 (methotrexate, sulfasalazine) Sandoz (leflunomide, methotrexate) Relevant research groups Arthritis Research UK Chronic Pain Policy Coalition Cochrane Musculoskeletal Group MRC Clinical Trials Unit National Institute for Health Research
 Others Department of Health NHS Barking & Dagenham CCG NHS Northumberland CCG Welsh Government NHS England 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non company commentators are invited to nominate clinical or patient experts.

National Institute for Health and Care Excellence

Matrix for the technology appraisal of Tofacitinib for treating moderate to severe active rheumatoid arthritis after the failure of disease-modifying anti-rheumatic drugs

Issue date: March 2017 Page 3 of 3

¹ Non company consultees are invited to submit statements relevant to the group they are representing.